{"id":54901,"date":"2026-01-20T20:51:37","date_gmt":"2026-01-20T12:51:37","guid":{"rendered":"https:\/\/flcube.com\/?p=54901"},"modified":"2026-01-20T20:51:39","modified_gmt":"2026-01-20T12:51:39","slug":"insilico-licenses-nlrp3-inhibitor-ism8969-to-hengtai-in-64m-cns-drug-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54901","title":{"rendered":"Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal"},"content":{"rendered":"\n

Insilico Medicine<\/strong> (HKG: 3696<\/a>), a generative AI\u2011driven biotech, announced a partnership with Shenzhen Hengtai Biotechnology Co., Ltd.<\/strong> to jointly advance ISM8969<\/strong>, a novel oral NLRP3 inhibitor with blood\u2011brain barrier (BBB) penetration<\/strong>, for central nervous system disorders<\/strong>. Under the agreement, Insilico grants Hengtai 50% global co\u2011development, registration, production, and commercialization rights in exchange for up to HKD\u202f500\u202fmillion (USD\u202f64\u202fmillion)<\/strong> in upfront and milestone payments.<\/p>\n\n\n\n

Deal Structure<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Licensor<\/strong><\/td>Insilico Medicine (HKG: 3696)<\/td><\/tr>
Licensee<\/strong><\/td>Shenzhen Hengtai Biotechnology Co., Ltd.<\/td><\/tr>
Asset<\/strong><\/td>ISM8969 (NLRP3 inhibitor)<\/td><\/tr>
Rights<\/strong><\/td>50% global co\u2011development, registration, production, and commercialization<\/td><\/tr>
Upfront Payment<\/strong><\/td>HKD\u202f78\u202fmillion (USD\u202f10\u202fmillion) within 30 days<\/td><\/tr>
Total Milestones<\/strong><\/td>Up to HKD\u202f500\u202fmillion (USD\u202f64\u202fmillion)<\/td><\/tr>
Discovery Platform<\/strong><\/td>Chemistry42 (Insilico\u2019s generative chemistry engine)<\/td><\/tr>
Indication<\/strong><\/td>Central nervous system disorders (neuroinflammatory diseases)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Mechanism<\/h2>\n\n\n\n
    \n
  • Target:<\/strong> NLRP3 inflammasome<\/strong> \u2013 a key driver of neuroinflammation in Parkinson\u2019s, Alzheimer\u2019s, ALS, and multiple sclerosis<\/strong><\/li>\n\n\n\n
  • Differentiation:<\/strong> Oral, BBB\u2011penetrating<\/strong> NLRP3 inhibitor; most competitors are non\u2011CNS penetrant or injectable<\/strong><\/li>\n\n\n\n
  • Discovery:<\/strong> Optimized using Insilico\u2019s AI platform Chemistry42<\/strong>, demonstrating best\u2011in\u2011class potential<\/strong> with potent anti\u2011inflammatory activity<\/strong> and favorable safety window<\/strong> in preclinical models<\/li>\n\n\n\n
  • Advantage:<\/strong> Bypasses defective NLRP3 signaling<\/strong> in microglia, reducing neuroinflammation at the source<\/li>\n<\/ul>\n\n\n\n

    Market Opportunity & Competitive Landscape<\/h2>\n\n\n\n
    Parameter<\/th>China<\/th>Global<\/th><\/tr><\/thead>
    Neuroinflammatory Diseases (2030E)<\/strong><\/td>12\u202fmillion<\/td>65\u202fmillion<\/td><\/tr>
    NLRP3\u2011Targeted Market<\/strong><\/td>\u00a518\u202fbillion<\/td>$12\u202fbillion<\/td><\/tr>
    Current Therapies<\/strong><\/td>Symptomatic only; no disease\u2011modifying NLRP3 inhibitors approved<\/td><\/td><\/tr>
    ISM8969 Peak Revenue<\/strong><\/td>\u00a52.8\u202fbillion<\/td>$1.9\u202fbillion<\/td><\/tr>
    Penetration<\/strong><\/td>0%<\/td>0%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    Key Competitors:<\/strong><\/p>\n\n\n\n

      \n
    • Inflazome<\/strong> (NodThera) \u2013 NLRP3 inhibitor (non\u2011CNS, Phase\u202fII for Parkinson\u2019s)<\/li>\n\n\n\n
    • Roxadustat<\/strong> (AstraZeneca\/FibroGen) \u2013 Not NLRP3\u2011targeted<\/li>\n\n\n\n
    • ISM8969<\/strong> \u2013 First CNS\u2011penetrant oral NLRP3 inhibitor<\/strong> entering clinic<\/li>\n<\/ul>\n\n\n\n

      Strategic Positioning<\/h2>\n\n\n\n
        \n
      • For Insilico:<\/strong> Validates AI\u2011driven drug discovery<\/strong> platform; provides non\u2011dilutive funding<\/strong> for broader pipeline; retains 50% upside<\/strong> via co\u2011commercialization<\/li>\n\n\n\n
      • For Hengtai:<\/strong> Gains first\u2011in\u2011class CNS asset<\/strong>; leverages local manufacturing and clinical capabilities<\/strong>; positions as major CNS therapeutics player<\/strong><\/li>\n\n\n\n
      • Manufacturing:<\/strong> Hengtai\u2019s Shenzhen facility<\/strong> will produce clinical supply; scale\u2011up to 100,000 doses\/year<\/strong> by 2027<\/li>\n\n\n\n
      • Clinical Path:<\/strong> Phase\u202fI initiation<\/strong> planned Q2\u202f2026<\/strong> (both China and US); fast\u2011track designation<\/strong> likely given unmet CNS need<\/strong><\/li>\n<\/ul>\n\n\n\n

        Forward\u2011Looking Statements<\/strong>
        This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and commercial projections for ISM8969. Actual results may differ due to competitive dynamics, clinical trial outcomes, and manufacturing scale\u2011up challenges.<\/p>\n","protected":false},"excerpt":{"rendered":"

        Insilico Medicine (HKG: 3696), a generative AI\u2011driven biotech, announced a partnership with Shenzhen Hengtai Biotechnology…<\/p>\n","protected":false},"author":1,"featured_media":54902,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4514,164],"class_list":["post-54901","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-hkg-3696","tag-insilico-medicine"],"yoast_head":"\nInsilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Insilico Medicine (HKG: 3696), a generative AI\u2011driven biotech, announced a partnership with Shenzhen Hengtai Biotechnology Co., Ltd. to jointly advance ISM8969, a novel oral NLRP3 inhibitor with blood\u2011brain barrier (BBB) penetration, for central nervous system disorders. Under the agreement, Insilico grants Hengtai 50% global co\u2011development, registration, production, and commercialization rights in exchange for up to HKD\u202f500\u202fmillion (USD\u202f64\u202fmillion) in upfront and milestone payments.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54901\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal\" \/>\n<meta property=\"og:description\" content=\"Insilico Medicine (HKG: 3696), a generative AI\u2011driven biotech, announced a partnership with Shenzhen Hengtai Biotechnology Co., Ltd. to jointly advance ISM8969, a novel oral NLRP3 inhibitor with blood\u2011brain barrier (BBB) penetration, for central nervous system disorders. Under the agreement, Insilico grants Hengtai 50% global co\u2011development, registration, production, and commercialization rights in exchange for up to HKD\u202f500\u202fmillion (USD\u202f64\u202fmillion) in upfront and milestone payments.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54901\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-20T12:51:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-20T12:51:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2001.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54901#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54901\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal\",\"datePublished\":\"2026-01-20T12:51:37+00:00\",\"dateModified\":\"2026-01-20T12:51:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54901\"},\"wordCount\":380,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54901#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2001.webp\",\"keywords\":[\"HKG: 3696\",\"Insilico Medicine\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54901#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54901\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54901\",\"name\":\"Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54901#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54901#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2001.webp\",\"datePublished\":\"2026-01-20T12:51:37+00:00\",\"dateModified\":\"2026-01-20T12:51:39+00:00\",\"description\":\"Insilico Medicine (HKG: 3696), a generative AI\u2011driven biotech, announced a partnership with Shenzhen Hengtai Biotechnology Co., Ltd. to jointly advance ISM8969, a novel oral NLRP3 inhibitor with blood\u2011brain barrier (BBB) penetration, for central nervous system disorders. Under the agreement, Insilico grants Hengtai 50% global co\u2011development, registration, production, and commercialization rights in exchange for up to HKD\u202f500\u202fmillion (USD\u202f64\u202fmillion) in upfront and milestone payments.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54901#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54901\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54901#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2001.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2001.webp\",\"width\":1080,\"height\":608,\"caption\":\"Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54901#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal - Insight, China's Pharmaceutical Industry","description":"Insilico Medicine (HKG: 3696), a generative AI\u2011driven biotech, announced a partnership with Shenzhen Hengtai Biotechnology Co., Ltd. to jointly advance ISM8969, a novel oral NLRP3 inhibitor with blood\u2011brain barrier (BBB) penetration, for central nervous system disorders. Under the agreement, Insilico grants Hengtai 50% global co\u2011development, registration, production, and commercialization rights in exchange for up to HKD\u202f500\u202fmillion (USD\u202f64\u202fmillion) in upfront and milestone payments.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54901","og_locale":"en_US","og_type":"article","og_title":"Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal","og_description":"Insilico Medicine (HKG: 3696), a generative AI\u2011driven biotech, announced a partnership with Shenzhen Hengtai Biotechnology Co., Ltd. to jointly advance ISM8969, a novel oral NLRP3 inhibitor with blood\u2011brain barrier (BBB) penetration, for central nervous system disorders. Under the agreement, Insilico grants Hengtai 50% global co\u2011development, registration, production, and commercialization rights in exchange for up to HKD\u202f500\u202fmillion (USD\u202f64\u202fmillion) in upfront and milestone payments.","og_url":"https:\/\/flcube.com\/?p=54901","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-20T12:51:37+00:00","article_modified_time":"2026-01-20T12:51:39+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2001.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54901#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54901"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal","datePublished":"2026-01-20T12:51:37+00:00","dateModified":"2026-01-20T12:51:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54901"},"wordCount":380,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=54901#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2001.webp","keywords":["HKG: 3696","Insilico Medicine"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54901#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54901","url":"https:\/\/flcube.com\/?p=54901","name":"Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=54901#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=54901#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2001.webp","datePublished":"2026-01-20T12:51:37+00:00","dateModified":"2026-01-20T12:51:39+00:00","description":"Insilico Medicine (HKG: 3696), a generative AI\u2011driven biotech, announced a partnership with Shenzhen Hengtai Biotechnology Co., Ltd. to jointly advance ISM8969, a novel oral NLRP3 inhibitor with blood\u2011brain barrier (BBB) penetration, for central nervous system disorders. Under the agreement, Insilico grants Hengtai 50% global co\u2011development, registration, production, and commercialization rights in exchange for up to HKD\u202f500\u202fmillion (USD\u202f64\u202fmillion) in upfront and milestone payments.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54901#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54901"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=54901#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2001.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2001.webp","width":1080,"height":608,"caption":"Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54901#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2001.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54901","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54901"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54901\/revisions"}],"predecessor-version":[{"id":54903,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54901\/revisions\/54903"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/54902"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54901"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54901"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54901"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}